Cognitive and neurological impairment in mood disorders

Marvel, Cherie L.; Paradiso, Sergio

doi:10.1016/s0193-953x(03)00106-0

Cited by 202 publications

(105 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A literatura demonstra principalmente alterações no processamento e organização do conteúdo perceptual, na memória operacional, na capacidade de atenção, nas funções executivas, no controle cognitivo e nos processos inibitórios, e na velocidade de processamento cognitivo (Harvey et al, 2004;Marvel & Paradiso, 2004;Philips, Drevets, Rauch & Lane, 2003a, 2003bRogers et al, 2004;Steele & Lawrie, 2004). O DSM-IV-TR (2002) inclui, entre os sintomas apresentados na depressão, retardo psicomotor e concentração diminuída.…”

Section: Aspectos Cognitivos Na Depressãounclassified

“…Além disso, os achados neuropsicológicos de alterações na cognição de pacientes deprimidos são corroborados por achados de neuroimagem (Drevets, 2003;Marvel & Paradiso, 2004). Aparentemente, em pacientes deprimidos, há uma variada alteração da neuroanatomia funcional (Murphy et al, 2003).…”

Section: Aspectos Cognitivos Na Depressãounclassified

“…Essas diferentes funções e seu desempenho em processos depressivos foram examinados na literatura (Chepenik, Cornew, & Farah, 2007;Dunkin et al, 2000;Harvey et al, 2004;Marvel & Paradiso, 2004;Murphy, Nimmo-Smith, & Lawrence, 2003;Rogers et al, 2004). Alterações no funcionamento cognitivo de pacientes deprimidos são corroboradas por estudos de neuroimagem que indicam alterações no funcionamento cerebral em pacientes deprimidos (Eugene et al, 2003;Rogers et al, 2004;Steele & Lawrie, 2004).…”

unclassified

See 2 more Smart Citations

Psicoterapia psicodinâmica e tratamento biológico com fluoxetina: comparação de resposta cognitiva em pacientes deprimidos

Bastos

Trentini

2013

Psic.: Teor. e Pesq.

View full text Add to dashboard Cite

RESUMO -A depressão é uma doença grave, com repercussões importantes no humor e na cognição. Tratamentos farmacológicos e/ou psicoterápicos estão comumente indicados. O presente estudo objetivou avaliar e comparar a cognição de pacientes deprimidos antes e após 12 meses de tratamento com fluoxetina ou psicoterapia psicodinâmica. Cento e oitenta pacientes foram divididos em dois grupos, e avaliados por meio da WAIS-III. Os resultados mostraram uma melhora significativa em diferentes subtestes da WAIS-III. A MANOVA indicou que há uma diferença significativa entre os grupos nas pontuações médias obtidas na reavaliação 12 meses após o início dos tratamentos. Os resultados sugerem que a psicoterapia psicodinâmica e a terapia com fluoxetina agem de forma diferente na cognição de pacientes deprimidos.Palavras-chave: psicoterapia psicodinâmica, fluoxetina, cognição, depressão Psychodynamic Psychotherapy and Biological Treatment with Fluoxetine: Comparison of Cognitive Response in Depressed PatientsABSTRACT -Depression is a serious illness with an important impact on humor and cognition. Pharmacological treatments and/or psychotherapy are commonly indicated. The present study aimed to compare cognition in adult patients diagnosed with depression before and after 12 months of treatment with fluoxetine or psychodynamic psychotherapy. One hundred and eighty depressed patients were divided into two treatment groups, and cognitively assessed with the WAIS-III. Results showed a significant improvement in different subtests of WAIS-III. MANOVA indicated that there is a significant difference between groups in the mean scores of the post-treatment assessment. The results suggest that psychodynamic psychotherapy and fluoxetine act differently on cognition of depressed patients.

show abstract

Section: Aspectos Cognitivos Na Depressãounclassified

unclassified

See 1 more Smart Citation

Psicoterapia psicodinâmica e tratamento biológico com fluoxetina: comparação de resposta cognitiva em pacientes deprimidos

Bastos

Trentini

2013

Psic.: Teor. e Pesq.

View full text Add to dashboard Cite

show abstract

“…Patients with depression and anxiety may experience cognitive dysfunction (Marvel & Paradiso, 2004). Since depressive symptoms and anxiety are frequently observed in patients with CFS (Harvey, Wessely, Kuh, & Hotopf, 2009), the possibility that these may contribute to impaired cognitive performance must be considered.…”

Section: Introductionmentioning

confidence: 99%

Neuropsychological Impairment in Female Patients with Chronic Fatigue Syndrome: A Preliminary Study

Santamarina-Pérez

Eiroá-Orosa

Rodríguez‐Urrutia

et al. 2013

Applied Neuropsychology: Adult

View full text Add to dashboard Cite

This study examines neuropsychological impairments associated with Chronic Fatigue Syndrome (CFS) and explores their association with related clinical factors.Sixty-eight women with CFS were assessed with a neuropsychological battery. Raw scores were adjusted for age and gender and converted to T-scores according to normative data extracted from a local sample of 250 healthy subjects.Neuropsychological dysfunction was calculated using summary impairment indices (proportion of test scores outside normal limits-T-score<40-for each cognitive domain).Finally, a linear regression was calculated to identify predictors of cognitive deficit, including intrinsic factors (level of fatigue and length of illness) and extrinsic factors (emotional factors, age and education) of the disease. Approximately 50% of scores showed impairment in attention and motor functioning, and nearly 40% in speed information processing and executive functioning. Fatigue predicted attention and executive functioning impairment, and emotional factors predicted verbal memory dysfunction. According to our findings, cognitive dysfunction in CFS could be explained by pathophysiological processes of the disease. One implication of this would be the need to identify homogeneous subgroups of CFS patients by taking into account common factors which, in turn, would help to identify more specific cognitive profiles, which could then serve to implement appropriate therapeutic measures accordingly.

show abstract

“…[11][12][13] There are declines in both TMT A and B performance in ageing. 10,[14][15][16][17][18][19][20] There is also evidence for performance deficits on TMT B in mood disorders 21 and in patients with schizophrenia and their relatives 18,[22][23][24][25][26][27] Family-based and twin-based studies have provided evidence for a genetic contribution to individual differences in trail making, estimating the heritability for trail making part A between 0.23 and 0.38, and between 0.39 and 0.65 for trail making part B. [28][29][30] A recent genome-wide association study (GWAS) of trail making part A and part B in a sample of around 6000 individuals did not find any genome-wide significant hits; 31 however, GWAS of other cognitive phenotypes have demonstrated that much larger sample sizes are required to reliably identify significant genetic loci.…”

Section: Introductionmentioning

confidence: 99%

Genetic contributions to Trail Making Test performance in UK Biobank

et al. 2017

View full text Add to dashboard Cite

The Trail Making Test (TMT) is a widely used test of executive function and has been thought to be strongly associated with general cognitive function. We examined the genetic architecture of the TMT and its shared genetic aetiology with other tests of cognitive function in 23 821 participants from UK Biobank. The single-nucleotide polymorphism-based heritability estimates for trail-making measures were 7.9% (part A), 22.4% (part B) and 17.6% (part B − part A). Significant genetic correlations were identified between trail-making measures and verbal-numerical reasoning (r g 40.6), general cognitive function (r g 40.6), processing speed (r g 40.7) and memory (r g 40.3). Polygenic profile analysis indicated considerable shared genetic aetiology between trail making, general cognitive function, processing speed and memory (standardized β between 0.03 and 0.08). These results suggest that trail making is both phenotypically and genetically strongly associated with general cognitive function and processing speed.Molecular Psychiatry advance online publication, 19 September 2017; doi:10.1038/mp.2017.189 INTRODUCTIONThe Trail Making Test (TMT) is widely used in both research and clinical settings as a test of some aspects of executive function. [1][2][3] The TMT is usually given as two parts, from which three measures are derived. In TMT Part A (TMT A), participants are required to connect an array of numbers in ascending order, by drawing a continuous line (trail) between them as quickly and accurately as possible. TMT Part B (TMT B) requires participants to connect an array of both numbers and letters in alternating ascending order (1, A, 2, B, 3, C and so on) with the same emphasis on speed and accuracy (Supplementary Figure 1). Subtracting TMT A completion time from that of TMT B (TMT B − A) is thought to allow the relative contributions of visual search and psychomotor speed to be parsed from the more complex executive functions (such as cognitive flexibility) required to alternate between numbers and letters. [4][5][6][7][8] TMT performance has been ascribed to a number of cognitive processes, 'including attention, visual search and scanning, sequencing and shifting, psychomotor speed, abstraction, flexibility, ability to execute and modify a plan of action, and ability to maintain two trains of thought simultaneously '. 9 It is considered a useful tool in research and clinical practice due to the sensitivity of the task (particularly TMT B and B − A) to frontal lobe damage (in some, but not other studies 10 ) and dementia. [11][12][13] There are declines in both TMT A and B performance in ageing. 10,[14][15][16][17][18][19][20] There is also evidence for performance deficits on TMT B in mood disorders 21 and in patients with schizophrenia and their relatives 18,[22][23][24][25][26][27] Family-based and twin-based studies have provided evidence for a genetic contribution to individual differences in trail making, estimating the heritability for trail making part A between 0.23 and 0.38, and between 0.39 and 0.65...

show abstract

Cognitive and neurological impairment in mood disorders

Cited by 202 publications

References 75 publications

Psicoterapia psicodinâmica e tratamento biológico com fluoxetina: comparação de resposta cognitiva em pacientes deprimidos

Psicoterapia psicodinâmica e tratamento biológico com fluoxetina: comparação de resposta cognitiva em pacientes deprimidos

Neuropsychological Impairment in Female Patients with Chronic Fatigue Syndrome: A Preliminary Study

Genetic contributions to Trail Making Test performance in UK Biobank

Contact Info

Product

Resources

About